
|Articles|July 26, 2002
Cancer vaccine gets orphan drug status
Antigenics Inc. reports the U.S. Food and Drug Administration grantedthe company's personalized cancer vaccine (Oncophage) orphan drug statusfor the treatment of metastatic melanoma. This offers the company potentialmarket exclusivity for seven years from FDA marketing approval.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
JAK Inhibitors Show Comparable Safety to TNF Antagonists
2
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
3
Medicus Pharma Completes Phase 2 Enrollment of D-MNA Study to Non-Invasively Treat BCC
4
Balancing Pathophysiology and Patient Lifestyle in Acne Management: Part 1
5


















